Journal Articles — George J. Hutton, M.D.

Dr. George J. Hutton has authored and co-authored 67 journal articles. They are listed here in reverse chronological order and grouped by published year. Click on the Expand plus symbol or Collapse minus symbol symbol to expand/collapse the list of journal publications by year, respectively.

Click on the PubMed link for details of that publication.

The cite count designates the number of times the publication has been cited by other papers indexed in Scopus. To access cite count information powered by Scopus, you must have a valid Texas Medical Center Resource Access Account. Need to register for access or forget password? Click here.

Sort By:    Year Published    Cite Count

2022

Collapse All | Expand All

Journal Articles Published in 2022 (n = 6)

Cite Count

PubMed

Reference

0     

Alkabie S, Tanweer O, Hutton GJ, Cuascut FX. Clinical reasoning: A 57-year-old man with stepwise progressive paraparesis, sensory loss, urinary retention, and constipation. Neurology. 2022;98(5):e555-60. PMID: 34799458.

0     

Choudhury NA, Castrodad-Molina RM, Hutton GJ, Cuascut FX. Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022;58:103498. PMID: 35007821.

0     

Li J, Chikermane SG, Earla JR, Hutton GJ, Aparasu RR. Factors associated with switching from injectable to oral disease modifying agents among patients with multiple sclerosis. Mult Scler Relat Disord. 2022;60:103703. PMID: 35278846.

0     

Li J, Zakeri M, Hutton GJ, Aparasu RR. Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022;66:104019. PMID: 35839614.

0     

Talwar A, Earla JR, Hutton GJ, Aparasu RR. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103308. PMID: 35158421.

0     

Talwar A, Earla JR, Hutton GJ, Aparasu RR. Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103308. PMID: 35158421.

2021

Collapse All | Expand All

Journal Articles Published in 2021 (n = 4)

Cite Count

PubMed

Reference

0     

Alkabie S, Castrodad-Molina R, Heck KA, Mandel J, Hutton GJ. The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021;50:102877. PMID: 33711579.

0     

Cuascut FX, Alkabie S, Hutton GJ. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021;53:103072. PMID: 34139459.

0     

Earla JR, Hutton GJ, Thornton DJ, Chen H, Johnson ML, Aparasu RR. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021;41(5):440-50. PMID: 33641232.

0     

Lee H, Nakamura K, Narayanan S, Brown RA, Nash RA, Griffith LM, et al. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021;54:103149. PMID: 34284316.

2020

Collapse All | Expand All

Journal Articles Published in 2020 (n = 8)

Cite Count

PubMed

Reference

0     

Earla JR, Hutton GJ, Thornton JD, Aparasu RR. Factors associated with prescribing oral disease modifying agents in multiple sclerosis: A real-world analysis of electronic medical records. Mult Scler Relat Disord. 2020;45:102334. PMID: 32629400.

0     

Earla JR, Hutton GJ, Thornton JD, Chen H, Johnson ML, Aparasu RR. Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis. Patient Prefer Adherence. 2020;14:2187-99. PMID: 33177813.

0     

Earla JR, Paranjpe R, Kachru N, Hutton GJ, Aparasu RR. Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020;16(12):1670-6. PMID: 32171597.

0     

Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020;26(6):741-9. PMID: 32463779.

0     

Fisher KS, Cuascut FX, Rivera VM, Hutton GJ. Current advances in pediatric onset multiple sclerosis. Biomedicines. 2020;8(4):. PMID: 32231060.

0     

Mercado V, Dongarwar D, Fisher K, Salihu HM, Hutton GJ, Cuascut FX. Multiple sclerosis in a multi-ethnic population in Houston, Texas: A retrospective analysis. Biomedicines. 2020;8(12):. PMID: 33255552.

0     

Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. PMID: 32498033.

0     

Wang KY, Carlton J, Guffey D, Hutton GJ, Moron FE. Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020;59(1):13-20. PMID: 31715512.

<2019

Collapse All | Expand All

Journal Articles Published in <2019 (n = 49)

Cite Count

PubMed

Reference

7

Cuascut FX, Hutton GJ. Stem cell-based therapies for multiple sclerosis: Current perspectives. Biomedicines. 2019;7(2):. PMID: 30935074.

0     

Yeo CJJ, Hutton GJ, Fung SH. Advanced neuroimaging in Balo's concentric sclerosis: MRI, MRS, DTI, and ASL perfusion imaging over 1 year. Radiol Case Rep. 2018;13(5):1030-5. PMID: 30228838.

43

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842-52. PMID: 28148635.

2

Mandel JJ, Goethe EA, Patel AJ, Heck K, Hutton GJ. Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016;369:51-2. PMID: 27653865.

0     

Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145-52. PMID: 25681448.

96

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159-69. PMID: 25546364.

9

Yapundich R, Applebee A, Bethoux F, Goldman MD, Hutton GJ, Mass M, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: A randomized controlled trial. Int J MS Care. 2015;17(3):138-45. PMID: 26052259.

0     

Hutton J, Hutton GJ. Congenital rubella with autism and evidence of a remote stroke. J Vaccines Vaccin. 2014;5:258. DOI: 10.4172/2157-7560.1000258.

3

Schurmann P, Basra S, Awar OG, Aguilar D, Basant A, Dragan E, et al. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord. 2014;3(3):408-12. PMID: 25876482.

0     

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-40. PMID: 23424159.

43

Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. IFN-beta induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neuroimmunol. 2012;242(1-2):39-46. PMID: 22112394.

0     

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-28. PMID: 23122652.

0     

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-39. PMID: 23122650.

0     

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-97. PMID: 22992072.

0     

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825-34. PMID: 22383228.

0     

Avila-Ornelas J, Avila M, Stosic M, Robles L, Prieto PG, Hutton GJ, et al. The role of postpartum intravenous corticosteroids in the prevention of relapses in multiple sclerosis. Int J MS Care. 2011;13(2):91-3. PMID: 24453710.

11

Stosic M, De Jesus P, McCarthy J, Hutton G, Rivera V. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011;77(5):505-7. PMID: 21775738.

0     

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15. PMID: 20089954.

26

Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010;4:219. PMID: 21152340.

8

Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):751-7. PMID: 20874252.

0     

Hutton GJ. Vitamin D and MS: implications for patient care. Pract Neurol. 2010;9:22-4.

72

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-41. PMID: 19204263.

0     

Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-71. PMID: 19847908.

3

Hutton GJ, Avila M, Suarez GA. Pneumocephalus after an epidural steroid injection. Clin Neurol Neurosurg. 2009;111(3):309-10. PMID: 19036497.

0     

Pachner AR, Warth JD, Pace A, Goelz S, INSIGHT Investigators. Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study. Neurology. 2009;73(18):1493-500. PMID: 19884577.

698

CAMMS Trial Investigators , Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-801. PMID: 18946064.

17

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, et al. Avonex Combination Trial in relapsing--remitting MS: Rationale, design and baseline data. Mult Scler. 2008;14(3):370-82. PMID: 18208877.

132

Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039-47. PMID: 18838462.

6

Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, et al. Autologous HSCT for advanced MS: Is the glass half-empty or really half-full? Brain. 2008;131(Pt 2):e89; author reply e90. PMID: 17908695.

343

Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727-32. PMID: 18541792.

99

Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-82 e5. PMID: 17976727.

1

Suarez Zambrano GA, Hutton GJ. Heart-shaped lesion secondary to neurosarcoidosis. Arch Neurol. 2008;65(10):1388-9. PMID: 18852359.

0     

 

Suarez GA, Hutton GJ, Rivera VM. Optic neuritis: Relation with multiple sclerosis. Acta Neurol Colomb. 2007;23:141-6.

0     

 

Suarez GA, Lotze TE, Hutton GJ, Rivera VM. Multiple sclerosis in the pediatric population. Acta Neurol Colomb. 2007;23:134-40.

64

Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):705-9. PMID: 17401392.

0     

 

Hutton G, Miller JR, Radue EW. MR finds widespread clinical use in MS diagnosis, management. Diagn Imaging. 2005;27:36-45.

0     

 

Hutton G, Miller JR, Radue EW. Multiple sclerosis: MRI in diagnosis, management, and monitoring. Appl Neurol. 2005;6(26-35):.

0     

Hutton G. Does "benign multiple sclerosis" really exist? Pract Neurol. 2005;4(3):27-9.

14

Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005;56:273-302. PMID: 15660513.

33

Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S3-11. PMID: 15596734.

0     

Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77-83. PMID: 14700647.

0     

Beck RW, Smith CH, Gal RL, Xing D, Bhatti MT, Brodsky MC, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004;61(9):1386-9. PMID: 15364684.

58

Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-39. PMID: 15223245.

0     

Optic Neuritis Study Group. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol. 2004;61(10):1538-41. PMID: 15477507.

0     

Rivera-Olmos VM, Hutton GJ, Breitbach WT. Discrepancia entre clinica e imagen: Esclerosis multiple en fase intermedia. Presentacion de un caso y revision del tema [Discrepancy between clinics and image techniques: Intermediate phase of multiple sclerosis. A case report and review of the literature]. Rev Mex Neuroci. 2004;5(2):158-62.

73

Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. PMID: 14985264.

22

Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10(5):499-506. PMID: 15471364.

0     

Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;121(7):944-9. PMID: 12860795.

35

Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002;24(12):1998-2021. PMID: 12581542.

See additional bibliometric measures (requires BCM login).